Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on ADC Therapeutics, Lowers Price Target to $5

Morgan Stanley analyst Matthew Harrison maintains ADC Therapeutics (NYSE:ADCT) with a Equal-Weight and lowers the price target from $7 to $5.
byBenzinga Newsdesk
January 24, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Matthew Harrison maintains ADC Therapeutics (NYSE:ADCT) with a Equal-Weight and lowers the price target from $7 to $5.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts